Products & Services · Product revenues, net
JOURNAVX — Product revenues, net
Vertex Pharmaceuticals JOURNAVX — Product revenues, net increased by 63.3% to $19.60M in Q3 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ2 2024
Last reportedQ3 2025
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful market adoption, effective commercialization, and growing patient demand for the therapy, while a decrease may signal competitive pressure, market saturation, or challenges in patient access.
Detailed definition
This metric represents the total net sales generated from the JOURNAVX product line after accounting for returns, rebate...
Peer comparison
Comparable to product-specific net revenue lines reported by other biotechnology and pharmaceutical companies for their key commercialized assets.
Metric ID:
vrtx_segment_journavx_product_revenues_netHistorical Data
4 periods
| Q2 '24 | Q3 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|
| Value | $0.00 | $0.00 | $12.00M | $19.60M |
| QoQ Change | — | — | — | +63.3% |
Range$0.00 – $19.60M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's journavx — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported journavx — product revenues, net of $19.60M in Q3 2025.
- What does journavx — product revenues, net mean?
- The total net sales revenue generated specifically from the JOURNAVX product.